BMS at the 63rd ASH Annual Meeting & Exposition

Delivering transformative research across major hematologic diseases

Intended for U.S. scientific audiences only.

The American Society of Hematology (ASH) annual meeting is the premier event in malignant and non-malignant hematology, and we remain ever-committed to researching and innovating for the blood cancer community. We look forward to sharing new data that demonstrate the strength of our innovative therapeutic platforms and modalities across our pipeline and portfolio in a broad range of hematologic diseases.  

Hear from Chief Medical Officer Samit Hirawat, M.D. and President of Research and Early Development Rupert Vessey, M.A., B.M., B.Ch., F.R.C.P., D.Phil. about the ways we’re working together to deliver transformative research across the most difficult-to-treat hematologic diseases, advancing care and improving patients’ lives.

Our Data at ASH 

Read more about our key data being presented at ASH.

Our Dedication to Advancing Cell Therapy, A Novel Personalized Medicine

Cell therapy, which includes therapies comprised of cells that are injected, implanted or grafted to treat disease, and use engineered cells to unlock new potential in the fight against cancer, is one of several key areas of research at Bristol Myers Squibb. Learn more about our dedication to cell therapies and personalized medicine here:

Looking to the Future of Cell Therapy >

Cell therapy has the potential to revolutionize the way scientists approach blood cancer treatment and is a core pillar of Bristol Myers Squibb’s cancer research efforts.

Our Science   

Over the last several decades, our innovative medicines have improved how cancer is treated, making long-term survival a possibility for more patients. But there is more work to do, and we strive to help more patients with our medicines, scientific discovery and investigational research. Learn about our approach.

The potential of our pipeline >

Anne Kerber, Mark Rolfe, and Teri Foy talk about the evolving hematologic cancer treatment landscape at Bristol Myers Squibb and the data to be presented at ASH 2021.

Pulling back the curtain on CD47 >

Learn more about CD47, the protein receptor which protects cells from being gobbled up by the human immune system and also highlights our mission of advancing the field of immunotherapy.

Building on today’s science to research medicines of tomorrow >

As a scientific research community, our work for people living with cancer is never done. Read about two examples of the research Bristol Myers Squibb is elevating to advance next-generation approaches in oncology and hematology.

Cell Therapy Resources >

Discover how cell therapies are unlocking new potential in cancer research and real-world application.

Protein Degradation Resources >

Learn about the science behind protein degradation and ongoing research that harnesses the power of this natural process. 

Exploring the Tumor Microenvironment >

Exploring the tumor microenvironment (TME) to better understand how cancer and the immune system coexist is a core component of Bristol Myers Squibb’s research and early development strategy.

Advancing Acute Myeloid Leukemia Research through Epigenetics >

Instead of killing the cell, hypomethylating agents, or HMAs, alter the signaling process by re-expressing genes to work properly again. Learn more about the treatment of AML through epigenetics. 

Our Commitment to Hematological Cancers

We are committed to improving the lives of patients and raising awareness of hard-to-treat blood cancers. We’ve brought life-changing medicines to patients worldwide and redefined treatment across many hematologic conditions. However, hundreds of thousands of patients still lack treatment options or their treatments have stopped working. For these patients, we keep innovating. Learn more here:

What is Myelodysplastic Syndrome? Is MDS a Form of Cancer? >

Possibly the only thing more frightening than being diagnosed with cancer is learning you have a form of the disease you’ve never heard of. Patients with MDS — a little-known blood cancer — are searching for new Myelodysplastic Syndrome treatment options.

Addressing Barriers to Clinical Trial Participation and Clinical Trial Diversity During COVID-19 and Beyond >

Hear from Chief Medical Officer Samit Hirawat, MD on how Bristol Myers Squibb has helped patients overcome barriers to clinical trial participation and advanced its R&D pipeline during the global pandemic.

Reflecting on our leadership in blood cancer: a Q&A with Winselow Tucker >

Every day, we leverage the latest science and technology to develop therapies that push beyond what is currently available to patients living with rare blood cancers and disorders.


Our research at ASH this year spans multiple blood cancers, therapeutic platforms, and clinical programs. Learn more about some of them below.

Manufacturing Cell Therapies – The BMS Difference >

Understand how innovation in manufacturing can deliver on the future of cell therapies.

Signal regulatory protein α (SIRPα) Fact Sheet >

Find out more about signal regulatory protein α (SIRPα) and how Bristol Myers Squibb is exploring the role SIRPα plays in cancer immunotherapy. 

Protein Degradation Fact Sheet >

Understand the process of cellular protein degradation.

The Path to a Protein Degrader Fact Sheet >

Explore how Bristol Myers Squibb is leveraging two different methods of protein degradation to provide more opportunities for breakthroughs and therapeutic strategies that could one day help patients.

Cell Therapy Fact Sheet >

Explore the various types of cell therapies and their role in Bristol Myers Squibb’s research and early development strategy. 

CAR T Cell Therapy Fact Sheet >

Discover how CAR T Cell Therapy is used to treat cancers.

Disease State and Treatment Infographics 

Download infographic resources on different types of blood cancers and therapies.